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Abstract The interaction of hexokinase with mitochondria
has emerged as a powerful mechanism in protecting many cell
types against cell death. However, the role of mitochondrial
hexokinase (mitoHK) in cardiac ischemia-reperfusion injury
has as of yet received little attention. In this reviewwe examine
whether increased binding of hexokinase to the mitochondrion
is also an integral component of cardioprotective signalling.
We discuss observations in cardiac mitochondrial activation
that directed us to the hypothesis of hexokinase cellular
redistribution with reversible, cardioprotective ischemia, sum-
marize the data showing that many cardioprotective interven-
tions, such as ischemic preconditioning, insulin, morphine and
volatile anesthetics, increase mitochondrial hexokinase bind-
ing within the intact heart, and discuss similarities between
mitochondrial hexokinase association and ischemic precondi-
tioning. Although most data indicate that mitochondrial
hexokinase may indeed be an integral part of cardioprotection,
a definitive proof for a causal relation between the amount of
mitoHK and cardiac ischemia-reperfusion injury in the intact
heart is eagerly awaited. When such relationship is indeed
observed, the association of hexokinasewith mitochondria will
offer an opportunity to develop new therapies to combat
ischemic cardiac diseases.
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Introduction
In the past two decades the mitochondria have revealed their
true nature in matters of life and death: not only are they the
power houses providing the necessary ATP for the high-energy
demand of highly organized multicellular organism, they are
also the cellular dictators of cell death. Interestingly, a
glycolytic enzyme, hexokinase (HK), has appeared as one of
the main gatekeepers of mitochondria-induced cell death
(Robey and Hay 2005). The interaction of hexokinase with
mitochondria results in suppression of cell death in many cell
types, and is probably one of the major mechanisms allowing
unrestricted growth of advanced cancer cells which are
protected against apoptosis (Pedersen 2008). Surprisingly,
almost all data on the protective role of HK against cell death
has been performed in cellular studies using primarily H2O2
as the oxidative injury stimulus. Little information exists as to
whether mitochondrial HK is protective against oxidative
injury under more physiological conditions. There is no
information available as to whether mitoHK may actually
provide survival benefit against ischemia-reperfusion (I/R) in
the intact heart. Whereas such an endogenous protection
mechanism offers a challenge to oncologists to combat in
cancer cells, it may offer a therapeutic opportunity for
cardiologists in the setting of cardiovascular ischemic disease.
This minireview focuses on recent evidence that mitochon-
drial hexokinase may be an integral component of cardio-
protective signalling in the heart.
Why could there be a role for mitochondrial HK
in cardioprotection?
Ischemic preconditioning is one of the strongest interven-
tions to bring the heart in a protected state. It entails the
application of short, reversible periods of ischemia
(<15 min) before a long, irreversible period of ischemia
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(>20 min) that results in cell death. It was discovered in
1986 by Murry and coworkers, who showed a reduction in
cell death by 60-70%. Many of the signals that induce
preconditioning converge on the mitochondrion (Murphy
and Steenbergen 2008). In addition, alterations in glycoly-
sis were also found to be a signature of ischemic
preconditioned hearts (Murry et al. 1986). We also found
this interaction between changes in glycolysis and mito-
chondrial function with reversible ischemia that induces
preconditioning. Work from our laboratory, focussing on
the activation of mitochondrial oxygen consumption with
instantaneous increases in workload (Van Beek et al. 1998),
demonstrated that glycolysis needs to be active to observe
changes in mitochondrial activation after a reversible period
of ischemia, which were not observed after irreversible
ischemia (Zuurbier and Van Beek 1997; Zuurbier and Ince
2002). Thus, alterations in glycolysis induced by reversible
ischemia resulted in a specific change in mitochondrial
activation that is characteristic of heart tissue in the
cardioprotective state. What type of changes in glycolysis
could possibly be associated with protection against I/R
injury? It has been reported that cardioprotection induced
by preconditioning resulted in decreased anaerobic glycol-
ysis and a decreased build-up of fructose-6-phosphate and
lactate, despite normal or even elevated levels of glucose
and glucose-6-phosphate during the sustained ischemia
(Murry et al. 1986; Jennings et al. 2001; Vogt et al.
2002). Thus preconditioning induced alterations in glycol-
ysis that are localized just after the first step of glycolysis,
i.e. the phosphorylation of glucose by HK. We have shown
that the decreased build-up of glycolytic intermediates after
the HK reaction is not due to an increased channelling of
these glycolytic intermediates into the pentose phosphate
pathway (Zuurbier et al. 2004), indicating that the changes
described above are probably the result of changes within
the control of glycolysis itself.
Regulation of glycolysis by ischemic preconditioning
may involve enzyme translocation, with HK being a likely
candidate. Especially the translocation of HK to the
mitochondria could explain many of the phenomena
described for ischemic preconditioning. First of all, binding
of HK to mitochondria protects against apoptosis induced
by oxidative stress (Majewski et al. 2004a, b; Pastorino and
Hoek 2003), which complements older literature by
Pedersen et al. 2002 showing that mitochondrial hexoki-
nase provides survival benefit in cancer. Thus, translocation
of HK to the mitochondrion may constitute part of the
cardioprotective phenotype of ischemic preconditioning. In
addition, the association of HK with mitochondria is
kinetically advantageous during normoxia (increased affin-
ity for the substrate ATP, decreased sensitivity to inhibition
by its product glucose-6-phopshate) and brings glycolysis
actually under the control of oxidative phosphorylation
(Wilson 1995). This may partly explain (in addition to the
effects of increased GLUT4 transporters in the sarcolemma)
the often observed increase in aerobic glycolysis of the
heart during normoxia following reversible periods of
ischemia (Zuurbier and Van Wezel 2008), and the acceler-
ated decrease in anaerobic glycolysis rate during the first
period of ischemia in preconditioned hearts (Murry et al.
1986). This increased coupling of glycolysis with oxidative
metabolism may result in a decreased anaerobic glycolytic
proton production and consequently attenuated acidosis
(Wilson 2003, Lopaschuk et al. 1993), as is usually
observed in preconditioned hearts.
It thus seems that increased association of hexokinase
with the mitochondria within the heart may explain many
of the phenomena observed with cardioprotection, offering
the arguments for a critical evaluation of the role of
mitochondrial HK in cardioprotection.
Cardioprotective interventions and mitochondrial
bound HK
In 2005, the first study was performed that examined
whether short, reversible periods of ischemia resulting in
ischemic preconditioning, was associated with HK translo-
cation to the mitochondria within the intact heart (Zuurbier
et al. 2005). It was demonstrated that hexokinase activity
decreased in the cytosol, whereas it increased in the
mitochondrial compartment of the ischemic preconditioned
heart. In addition, two other well-known cardioprotective
interventions were examined: morphine and insulin admin-
istration. Both morphine and insulin were also able to
redistribute HK from the cytosol to the mitochondrial
compartment. That HK translocation involved in cardio-
protective signalling was further collaborated by a subse-
quent study in in vivo rat hearts (Zuurbier et al. 2008). It
was shown that well-known cardioprotective anesthetics
such as isoflurane and sevoflurane are able to keep
hexokinase at the mitochondria during sedation, whereas
other non-cardioprotective anesthetics such as ketamine
resulted in increases of cytosolic HK as compared to
conscious, non-anesthetized, animals. These data clearly
demonstrated that translocation of hexokinase to the
mitochondria with ischemic preconditioning is operative
within the intact heart and that this may very well constitute
a general end-effector of cardioprotective interventions.
Current knowledge of the cellular signalling pathways
that initiate ischemic preconditioning suggests a major role
for activation of so-called survival kinases such as the
PI3K-Akt cascade (Tong et al. 2000) and the JAK-STAT
pathway (Hattori et al. 2001). Several cellular studies by
Majewski et al. (2004a, b) have demonstrated that activated
Akt results in translocation of HK to the mitochondria. It
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has been suggested that activated Akt resulted in phosphor-
ylation and thereby inhibiting GSK-3β, and that this
inhibition resulted in the translocation of HK to the
mitochondria (Pastorino et al. 2005). Alternatively, it is
also possible that activated Akt directly phosphorylates HK in
the cytosol and that this facilitates HK association with
mitochondria (Miyamoto et al. (2008). Thus, Akt activation
may closely correspond with mitochondrial HK translocation.
In addition, it has been shown that Akt activation has a
biphasic behaviour with ischemic preconditioning (Hausenloy
et al. 2005): Akt is activated before and after, but not during
the sustained ischemic period in preconditioned hearts. Fully
in line with this, we have observed similar biphasic behaviour
for mitochondrial HK activity with ischemic preconditioning:
mitochondrial HK activity was increased before and after, but
not during the sustained ischemic period in ischemic
preconditioned hearts as compared to control hearts (Gürel
et al. 2009).
In conclusion, cardioprotective signalling in the intact heart
appears to be associated with increases of hexokinase at the
level of the mitochondria in a fashion similar as to that found
to provide survival benefit in other cell types including
malignant tumour cells, and that the HK translocation may be
regulated by the RISK pathway (Fig. 1).
Possible mechanisms of mitoHK-mediated
cardioprotection against I/R injury
Hexokinase may offer protection against ischemia-
reperfusion injury by increases in its activity, independent
of its binding to mitochondria. The increased HK activity
may provide protection through improved ATP production
by activating glycolysis. In an elegant study by Sun et al.
(2008) it was shown that overexpression of truncated HK
proteins lacking the mitochondrial binding domains could
indeed partly explain the protective effects of overex-
pressed full length HK proteins against H2O2 treatment in
HEK293 cells. Similarly, overexpressing of yeast hexoki-
nase, which does not bind to mitochondria, protected
hypoxic cardiomyocytes against contractile dysfunction
(Ye et al. 2005). However, whether these protective effects
of increased HK activity observed in cellular studies (where
glucose is usually the sole substrate provided) translate to a
more physiological model of ischemia-reperfusion in the
intact heart ischemia is unclear. Liang et al. (2002) has
shown that overexpressing yeast hexokinase did not protect
against contractile dysfunction following hypoxia in the
Langendorff-perfused mouse heart. Thus it is unclear
whether an increased HK activity per se will always cause
survival benefit against an ischemia-reperfusion insult in
the intact heart. This is commensurate with the well-known
dual role (detrimental or beneficial) of anaerobic glycolysis
in cardiac ischemia-reperfusion injury (Cross et al. 1996).
I/R injury is initiated by calcium overload and generation
of reactive oxygen species, which result in activation of
proteases (e.g. caspases, calpains), mitochondrial depolar-
ization and mitochondrial permeability transition (MPT)
pore opening. Although still elusive, the MPT pore is
suggested to be composed of VDAC, ANT, cyclophilin D
and HK (Green and Kroemer 2004). One mechanism,
through which mitochondrial binding of HK could be
protective, is by occupying MPT-VDAC binding sites
which otherwise would be occupied by the pro-apoptotic
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Fig. 1 Proposed view for how
cardioprotective interventions
through cellular signalling trans-
locate hexokinase (HK) to the
mitochondria and how increases
in mitochondrial HK (mitoHK)




OMM outer mitochondrial mem-
brane, CypD cyclophilin D, ANT
adenine nucleotide translocator,
VDAC voltage dependent anion
channel, IRS insulin receptor
substrate, GPCR G protein-
coupled receptor, PI3K phos-
phoinositide 3-kinase, PKC
protein kinase C, GSKhh-3β
glycogen synthase kinase, ∆ψ
mitochondrial membrane poten-
tial, ROS reactive oxygen species
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proteins Bax/Bak (Pastorino and Hoek 2008).Whether
VDAC is an essential component in this scenario was
recently contested by Chiari et al. (2008), showing that HK
detachment from mitochondria triggers apoptosis indepen-
dent of VDAC. These authors imply that mitoHK protects
by affecting the configuration of the two other components
of the MPT, i.e. ANT and/or cyclophylin D, although the
precise mechanism was not characterized. One possibility
may be that hexokinase activity drains mitochondrial ATP
for the phosphorylation of glucose, thereby facilitating ATP
to move out of the mitochondria and ADP to move in, and
stimulating ATP/ADP exchange. It has been shown by Van
der Heiden et al. (1999) that an early event in apoptosis is a
defect in ATP/ADP exchange.
Alternatively, an attractive hypothesis is that mitoHK
serves as a specific antioxidant against mitochondrial
radical production. Da-Silva et al. (2004) have demonstrat-
ed that mitochondrial bound hexokinase reduced mitochon-
drial membrane potential and ROS production in brain
mitochondria. Similar findings have been recently observed
in heart mitochondria (Santiago et al. 2008), and the
reduction of oxidative stress has been recently implicated
as a likely candidate for inhibition of the MPT with
ischemic preconditioning (Clarke et al. 2008). Increases of
mitochondrial hexokinase functionally mimics increases in
mitochondrial uncoupling, a phenomenon which is current-
ly regarded as one of the mechanisms providing ischemic
preconditioning-induced cardioprotection (Sack 2006). Fi-
nally, it has recently been reported that hearts of hypoxia-
tolerant fish have elevated amounts of HK bound to
mitochondria. These authors proposed that the high level
of mitochondrial HK serves to create microenvironments
with a low ATP/ADP ratio, which could lead to the opening
of mitoKATP channels that occur in hypoxic-tolerant fish
hearts (Treberg et al. 2007). Such an opening of mitoKATP
channels also figures as one of the main ischemic
preconditioning triggering mechanism (Garlid et al. 1997).
Overall, many of the purported protective mechanisms
against cell death of mitochondrial bound HK (Fig. 1) are
similar to the mechanisms through which ischemic pre-
conditioning and other cardioprotective interventions are
currently proposed to operate.
Conclusions
We have reviewed here the current literature which shows
that the binding of hexokinase to mitochondria is induced
during many cardioprotective interventions in the intact
heart. There are also many similarities between the cellular
signalling which leads to the cardioprotective mechanism of
ischemic preconditioning, and the cellular signalling which
leads to the protective mechanisms of HK translocation and
its binding to the mitochondria, thus further supporting a
role of HK in cardioprotection. Further studies examining a
causal relationship between the amount of mitoHK and
cardiac ischemia-reperfusion injury are necessary to test the
hypothesis that mitochondrial hexokinase is indeed an
important player in the field of cardioprotection and cardiac
ischemic diseases.
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